Takeaways:

  • Firebrick Pharma is targeting a “pivotal year” in 2026 as it accelerates Nasodine international expansion.
  • Nasodine is a povidone-iodine (PVP-I) nasal spray supported by Clinical Trials and peer-reviewed publications.
  • The product launched in the USA in April 2024 and Singapore in June 2024.
  • Nasodine Throat Spray launched in Singapore and Fiji in early 2026.
  • Regulatory submissions are progressing in the Philippines and two additional Southeast Asian markets.

Firebrick Pharma (ASX:FRE) has positioned 2026 as a defining year for its Nasodine respiratory virus product portfolio, accelerating international commercial expansion across Southeast Asia and other regulator-friendly markets. The company has historically faced a more challenging regulatory environment for nasal sprays in some Western jurisdictions, with the Australian and US therapeutic regulatory frameworks applying more conservative pathways for over-the-counter respiratory virus claims.

Asia and the Pacific have provided more straightforward commercial pathways, and Firebrick has prioritised these markets in 2026 as it builds out the Nasodine global footprint.

Nasodine: the PVP-I nasal spray

Firebrick was founded in 2012 with the mission to develop a nasal spray based on povidone-iodine (PVP-I) for use as a treatment for the common cold. PVP-I has decades of clinical history as an antiseptic, with strong viral inactivation properties supported by extensive published research.

Nasodine is the company’s premier product and is described by Firebrick as the only PVP-I nasal spray supported by a decade of R&D, proven safety in controlled human Clinical Trials and a growing list of peer-reviewed publications. Viral inactivation studies have confirmed Nasodine rapidly kills all respiratory viruses tested.

USA and Singapore launches set the foundation

In 2024, Firebrick successfully completed commercial-scale Manufacturing of Nasodine and the product was launched in the United States in April and in Singapore in June. The US launch operates under specific regulatory frameworks for over-the-counter products with PVP-I as an active ingredient, while Singapore’s framework provided a more direct regulatory pathway.

The 2024 launches established the foundation for international expansion. They also provided the Manufacturing and commercial infrastructure required to support multi-market scaling — a significant prerequisite for 2026 momentum.

2026 expansion: Throat Spray and new markets

In early 2026, Firebrick began launching Nasodine Throat Spray, a follow-on product designed to protect against and treat sore throats. Launches have already commenced in Singapore and Fiji, leveraging existing distribution relationships and Brand Recognition.

The company is pursuing regulatory approval for Nasodine Nasal Spray in the Philippines, one of Southeast Asia’s largest healthcare markets. Approvals in two additional regional countries are also anticipated. The Philippines opportunity is particularly notable given the country’s large population, growing healthcare spending and preference for established antiseptic products.

Why the Southeast Asia focus matters

Southeast Asian healthcare markets have grown significantly through the post-Pandemic period, with rising consumer health spending, growing distribution networks and an evolving regulatory environment. Many regional regulators have applied more direct pathways for established active ingredients such as PVP-I, particularly when supported by clinical evidence.

For ASX-listed pharma companies, Asian market exposure provides Revenue Diversification and lower regulatory complexity than Western markets. Firebrick’s focus on Singapore, Fiji and the Philippines reflects the broader trend of Australian biotechs targeting Asian commercialisation.

Sector context: ASX OTC and respiratory pharma

The ASX hosts a small but active cohort of over-the-counter (OTC) and consumer healthcare-focused pharma companies. Firebrick’s positioning is differentiated by its single-product focus and the active ingredient’s established safety profile, which reduces development risk relative to novel chemical entities.

Respiratory virus product Demand has shifted through the post-Pandemic period, with consumer awareness elevated relative to pre-2020 levels. Products that combine prophylactic and treatment positioning, such as PVP-I sprays, have benefited from this awareness shift.